For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a reduced risk for certain complications of DR, according to a study published online Aug. 11 in JAMA Network Open.
This article was originally published on MedicalXpress.com